MedTrace Logo

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

NCT00052403 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-01-16

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

monoclonal antibody anti-anb3 integrin

PROCEDURE

anti-cytokine therapy

PROCEDURE

antiangiogenesis therapy

PROCEDURE

antibody therapy

PROCEDURE

biological response modifier therapy

PROCEDURE

growth factor antagonist therapy

PROCEDURE

monoclonal antibody therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Barbara Ann Karmanos Cancer Institute

    lead OTHER

Principal Investigators

  • Patricia LoRusso, DO · Harper Hospital

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00052403 on ClinicalTrials.gov